Best Biotech Catalyst & FDA Calendar Tools (2026)
If you trade or invest in biotech, you already know the game is won or lost around catalysts — FDA decisions, clinical trial readouts, and financing events. The right catalyst-tracking tool tells you what is coming, how likely it is to go your way, and what could go wrong. This guide compares the main biotech catalyst and FDA calendar tools in 2026, what each does best, and how to choose.
Prices and features change often — always confirm current details on each provider’s site. This comparison focuses on approach and positioning rather than exact, time-sensitive pricing.
What a biotech catalyst tool should do
The best tools cover four jobs:
- Catalyst calendar — upcoming PDUFA dates, trial readouts, and FDA decisions in one place.
- Approval context — some estimate probability of approval; the best explain why.
- Dilution & runway — dilution is the biggest hidden risk in small-cap biotech, so cash runway matters.
- Alerts — catalysts move stocks in minutes, so timely notifications count.
Comparison at a glance
| Tool | Best for | Free public data? | Standout |
|---|---|---|---|
| BioRadar | Transparent approval odds + free public data | Yes — calendars & stock pages public | Explained Probability-of-Approval score + cash-runway from real operating burn |
| BiopharmCatalyst | Long-running FDA calendar & community | Limited | Established brand, historical catalyst calendar |
| BiopharmaWatch | Breadth & institutional data | Limited | 1,000+ companies, options flow, hedge-fund tracking |
| BPIQ | Deep catalyst database | Limited | Large drug-asset database, model portfolios |
| FDA Tracker | Trial-level analytics | Limited | Clinical trial tracker & screening |
The tools in detail
BioRadar
BioRadar focuses on making FDA catalysts understandable, not just listing them. Every upcoming decision gets a Probability of Approval score with its component breakdown shown — base rate, therapeutic area, prior CRL, cash-runway risk — so you can judge the estimate rather than trust a black box. Cash runway is computed from real operating cash flow (not raw balance changes), and much of the data — the PDUFA calendar, historical outcomes, stock pages and pipeline pages — is public without an account. Full access (scanner, AI briefings, unlimited watchlist, email alerts) is a 7-day free trial, then $15/month.
Best for: traders who want transparent approval odds, dilution awareness, and to research freely before paying.
BiopharmCatalyst
One of the longest-running biotech catalyst calendars, with an established user base and a well-known FDA calendar. A solid choice for traders who value a familiar, community-backed catalyst calendar. Access to the full calendar and tools is subscription-based.
Best for: traders who want an established, brand-name catalyst calendar.
BiopharmaWatch
Broad coverage across a large universe of companies with many data points, including institutional signals such as options flow and hedge-fund positioning, plus probability-of-approval cards. A good fit if you want breadth and smart-money data alongside the calendar.
Best for: investors who want wide coverage and institutional/options data.
BPIQ
A deep catalyst and drug-asset database covering hundreds of companies, with model portfolios and screening across multiple subscription tiers. Strong for research-heavy users who want a large searchable database.
Best for: research-oriented investors who want a large catalyst database.
FDA Tracker
Leans toward clinical-trial-level analytics and screening — useful for investigating the trials behind upcoming catalysts by condition, phase and completion date.
Best for: users focused on trial-level detail.
How to choose
- Want to understand approval odds, not just see them? Look for a tool that explains its probability estimate. BioRadar shows the full breakdown.
- Worried about dilution? Prioritise a tool with genuine cash-runway analysis based on operating burn.
- Want to research before paying? Choose a tool with meaningful free/public data or a no-risk trial.
- Need institutional/options data? Broader platforms cover that at a higher price point.
Where BioRadar fits
BioRadar is built for the individual biotech trader who wants transparent approval odds, dilution awareness, and the freedom to research before subscribing — at a lower price point than most institutional-grade platforms. If you want the widest possible universe or deep options-flow data, a larger platform may suit you better; if you want a clear, honest read on the next FDA decision and its risks, that is exactly what BioRadar is designed for.
See it in action: upcoming FDA decisions, how biotech stocks move around FDA decisions, or the PDUFA calendar.
Frequently asked questions
What is the best biotech catalyst calendar tool?
There is no single best tool for everyone. BiopharmCatalyst is a well-established catalyst calendar, BiopharmaWatch and BPIQ offer broad coverage and deep databases, and BioRadar focuses on transparent approval-probability scores, cash-runway analysis and free public data with a low-cost trial. The best choice depends on whether you prioritise breadth, institutional data, transparency, or price.
Are there free biotech FDA calendar tools?
Most catalyst platforms keep their calendars behind a login or paywall. BioRadar publishes its PDUFA calendar, historical outcomes, stock pages and pipeline pages publicly without an account, and offers full features on a 7-day free trial. Always check each provider for current free-access terms.
What should I look for in a PDUFA calendar tool?
Look for four things: a reliable upcoming-catalyst calendar, an approval-probability estimate that explains its reasoning, genuine cash-runway and dilution analysis, and timely alerts. Tools that only list dates without context leave you to do the risk analysis yourself.